U.S. Diagnostic Labs Market Size, Share, By Lab Type, Testing Services, Diseases, and Revenue Source - Trends, Analysis, and Forecast till 2035

U.S. Diagnostic Labs Market Size, Share, By Lab Type, Testing Services, Diseases, and Revenue Source - Trends, Analysis, and Forecast till 2034

Diagnostic laboratory is a facility, which is equipped with reagents, apparatus for performing diagnostic test and for detecting human infection. The rise in healthcare industries, rapid test kits, and rising cases of chronic diseases are leading cause of the U.S. diagnostic labs market growth. Another elements driving the market diversification is increasing rates of allergic diseases. Additionally, throughout the forecast period, it is assessed that company alliances also generate possibilities for market augmentation.

U.S. Diagnostic Labs Market Report Highlights:

• The market is estimated to grow at USD 51.1 billion in 2035.
• The U.S. diagnostic labs market size was evaluated at USD 33.0 Billion in 2024.
• The market is extending at a CAGR of 2.0%.
• On the basis of lab type, the market is dominated by the hospital-based labs segment.
• By testing services, the COVID-19 testing segment is leading the market.
• Under diseases, the oncology segment holds the largest market share.
• The healthcare plan revenue source segment is expected to lead the market during the projected period.

Key Benefits of Purchasing This Report

Gain valuable insights into revenue projections for the overall market and its sub-segments, benefiting industry leaders and new entrants.

Enhance your understanding of the competitive landscape to refine business positioning and optimize go-to-market strategies.

Stay informed on the latest trends in the U.S. Diagnostic Labs Market, including key drivers, challenges, opportunities, and barriers.

U.S. Diagnostic Labs Market Key Highlights:

In October 2024, LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, bringing the total number of its CLIA-certified labs in the U.S. to four. This acquisition strengthens LabGenomics’ strategic development and expands its diagnostic services nationwide, particularly in molecular technology.

In July 2024, the U.S. Food and Drug Administration (FDA) has approved a blood test that can help detect colorectal or colon cancer. This expands options for screening one of the most deadly diseases affecting younger populations worldwide.

Segmentation:

By Lab Type:

• Single/Independent Laboratories
• Hospital-Based Labs
• Physician Office Labs
• Others

By Testing Services:

• Physiological Function Testing
• General & Clinical Testing
• Esoteric Testing
• Specialized Testing
• Non-Invasive Testing
• COVID-19 Testing
• Others

By Diseases:

• Cardiology
• Oncology
• Neurology
• Orthopedics
• Gastroenterology
• Gynecology
• Odontology
• Others

By Revenue Source:

• Healthcare Plan
• Out-of-Pocket
• Public System

Us Diagnostic Labs Market Competitive Landscape

• ARUP LABORATORIES
• Quest Diagnostics Incorporated
• MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
• MaineHealth
• NORTON HEALTHCARE
• RADNET INC.
• American Oncology Network
• NATERA, INC
• BIOREFERENCE HEALTH, LLC
• LifeLabs
• NeoGenomics Laboratories
• PRECISION BIO LABORATORIES INC.

Key Questions Answered in This Report

1. What was the size of the U.S. Diagnostic Labs Market in 2024?

2. What is the expected growth rate of the U.S. Diagnostic Labs Market during 2025-2035?

3. What are the key factors driving the U.S. Diagnostic Labs Market?

4. What is the breakup of the U.S. Diagnostic Labs Market based on the distribution channel?

5. What are the key regions in the U.S. Diagnostic Labs Market?

6. Who are the key players/companies in the U.S. Diagnostic Labs Market?

7. What are the drivers, restraints, and opportunities in the U.S. Diagnostic Labs Market?